Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Bavarian Nordic A/S

Bavarian Nordic is a biotechnology company that develops, manufactures and commercializes vaccines.

Bavarian Nordic

For us, it is all about improving and saving lives
Improving and saving lives through innovative vaccines is at the heart of what we do in Bavarian Nordic, and we have more than 25 years of experience in developing life-saving vaccines. We are a fully integrated vaccine company focused on the development, manufacturing and commercialization of our vaccines-

We are a global leader in smallpox and mpox vaccines, which have been developed through our long-standing partnership with the U.S. Government to enhance the public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. 

Our values – our Bavarian Nordic DNA, as we call it – is what guides our actions. We act as persistent pioneers, we are embracing change, we value being boosted by the team, and we believe in protecting lives every day. If that is also a part of your DNA, we invite you to join us in Bavarian Nordic!

We are a global team of more than 1,400 dedicated people with diverse backgrounds and viewpoints who are bound together by our commitment to protect lives every day. We believe in creating an inclusive and flexible workplace with a strong focus on personal and professional development, because we need each other to take things further. 

We operate in a world in constant flux and always explore new opportunities. So, if you are open-minded and have the willpower to succeed, we might just be a perfect fit.

See your career opportunities at www.bavarian-nordic.com/careers

Nabobil.no

European Investment Bank

We are proud to announce our commitment to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of our mpox vaccine.

In partnership with Gavi, the Vaccine Alliance, World Health Organization and UNICEF we will work to facilitate the availability of doses in response to the ongoing outbreak in the DRC and other African countries.

Read more: https://lnkd.in/dfKtvq-y

It calls for celebration. 

Over the past months, we have submitted a record-high number of regulatory submissions and succeeded with the commercial launch of our mpox vaccine in the US. Undoubtedly, these are pivotal moments for us at Bavarian Nordic, shaping the future of our company.

So, what better occasion than bringing colleagues together across locations and geographies to celebrate their dedication and hard work. Here’s to many more milestones and continued success!


#BavarianNordic #Boostedbytheteam #ProtectingandSavingLives #Pharma

Today, we announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of our vaccine candidate for immunization to prevent disease caused by #chikungunya virus infection in individuals 12 years of age and older. 

“The MAA marks our second major submission in just a few weeks as part of our efforts to launch the chikungunya vaccine next year in the U.S. and Europe. Chikungunya, like other mosquito-borne infectious diseases, represents an increasing public health threat due to factors such as climate-change, but also resulting from improved disease surveillance and diagnosis. Our vaccine candidate is designed for ease of use in individuals 12 years of age and older at risk of chikungunya virus and represents an important contribution to the development of preventative solutions against this debilitating disease,” said Paul Chaplin, President and CEO of Bavarian Nordic.

Read more: https://lnkd.in/dcBEp5jg

Sustainability is an integral part of our strategy and business and now we have also converted our undrawn credit facility into a sustainability-linked loan. This means the interest rate margin will adjust based on the success of our sustainability ambitions:

· Access to Medicine: Develop and execute a strategy to expand access to our vaccines.
Responsible Supply Program: Increase the number of key suppliers undergoing third-party audits on environmental, social, and governance parameters.
· Greenhouse Gas Emissions: Reduce Scope 1 and 2 greenhouse gas emissions compared to our 2023 baseline.

We are proud of this commitment as a significant milestone in our efforts to deliver on our sustainability ambitions.

#savinglives #communities #vaccines #socialresponsiblity #sustainability #GlobalHealth #ESG

Say hi to our BNPride community group. BNPride is the name of our Employee Resource Group, founded by two of our employees, Mark Clarke and Virginia Fitt, with the dedication to support and raise awareness of LGBTQIA+ topics.

The group consists of eight members, with fellow colleagues invited to join. They meet every two weeks to connect on lived experiences while helping spark ideas that create positive change and inclusivity. 

Some of our BNPride members shared their stories and why DE&I is important to them. ⬇ 


#PrideMonth #BNPride #Inclusion #Allyship #BavarianNordic

Last week, we had the pleasure of welcoming the Danish Minister for the Interior and Health, Sophie Løhde to our manufacturing facility in Denmark together with MEP Morten Løkkegaard and vice mayor of Helsingør Kommune, Mette Lene Jensen. 

The visit provided a great opportunity for us to highlight our company’s role on both a local and a global scale. Our CFO Henrik Juuel, CPO Anu Helena Kerns, and Head of Drug Substance Production Andrea Dahle-Morville met with the delegation to discuss vaccines as part of the critical infrastructure across borders and our contribution to recent EU initiatives such as HERA and rescEU, during and after the mpox outbreak. The meeting also highlighted our increased global presence and need for improving access to talents to help drive further growth and success for the Danish life-science industry.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	1.21B -	1.22B 0.36%	1.02B 16.13%	1.01B 1.35%	1.37B 36.10%	500.62M 63.46%	662.49M 32.33%	1.85B 179.61%	1.90B 2.46%	3.15B 66.02%	7.06B 123.99%
cost of revenue	484.70M -	495.08M 2.14%	415.14M 16.15%	297.79M 28.27%	290.62M 2.41%	255.12M 12.22%	354.76M 39.06%	1.20B 236.88%	1.33B 11.08%	1.45B 9.19%	2.54B 74.92%
gross profit	727.80M -	721.73M 0.83%	605.42M 16.12%	708.95M 17.10%	1.08B 52.27%	245.50M 77.26%	307.73M 25.35%	657.29M 113.59%	570.32M 13.23%	1.70B 198.30%	4.52B 165.79%
selling and marketing expenses	40.78M -	45.11M 10.61%	42.27M 6.29%	38.56M 8.78%	39.88M 3.42%	33.73M 15.43%	53.48M 58.56%	285.78M 434.41%	191.78M 32.89%	212.93M 11.03%	331.58M 55.72%
general and administrative expenses	156.99M -	181.02M 15.31%	174.79M 3.44%	174.21M 0.33%	168.06M 3.53%	179.96M 7.08%	173.42M 3.63%	278.14M 60.39%	292.92M 5.31%	376.02M 28.37%	540.85M 43.83%
selling general and administrative expenses	197.77M -	226.13M 14.34%	217.06M 4.01%	212.77M 1.97%	207.94M 2.27%	213.68M 2.76%	226.89M 6.18%	563.93M 148.54%	484.70M 14.05%	588.96M 21.51%	815.78M 38.51%
research and development expenses	496.61M -	478.93M 3.56%	386.81M 19.23%	463.17M 19.74%	518.40M 11.93%	386.30M 25.48%	409.28M 5.95%	341.42M 16.58%	399.16M 16.91%	1.18B 196.40%	2.21B 86.67%
other expenses								-627.65M -
cost and expenses	1.18B -	1.20B 1.79%	1.02B 15.09%	973.74M 4.44%	1.02B 4.44%	855.10M 15.92%	990.93M 15.89%	1.47B 48.63%	2.21B 50.15%	3.22B 45.68%	5.56B 72.58%
operating expenses	694.38M -	705.06M 1.54%	603.87M 14.35%	675.94M 11.94%	726.34M 7.46%	599.98M 17.40%	636.18M 6.03%	277.70M 56.35%	883.86M 218.28%	1.77B 100.49%	3.02B 70.66%
interest expense	6.49M -	6.28M 3.37%	6.53M 4.11%	7.06M 8.13%	5.68M 19.62%	14.53M 155.92%	18.49M 27.25%	177.00M 857.29%	152.06M 14.09%	119.69M 21.29%	15.03M 87.44%
ebitda	64.06M -	65.66M 2.50%	127.03M 93.47%	112.71M 11.28%	345.09M 206.18%	-277.87M 180.52%	-259.39M 6.65%	809.77M 412.19%	125.00M 84.56%	395.40M 216.33%	2.05B 418.80%
operating income	17.84M -	20.71M 16.11%	83.51M 303.13%	67.34M 19.36%	307.56M 356.71%	-319.51M 203.89%	-316.43M 0.96%	449.62M 242.09%	-263.31M 158.56%	-3.85M 98.54%	1.50B 39,047.28%
depreciation and amortization	46.22M -	44.95M 2.75%	43.52M 3.16%	45.36M 4.23%	37.53M 17.27%	41.64M 10.95%	57.05M 37.00%	360.15M 531.34%	388.31M 7.82%	399.25M 2.82%	553.82M 38.72%
total other income expenses net	-11.64M -	43.65M 474.99%	-5.88M 113.47%	-27.79M 372.67%	-5.28M 81.01%	-37.13M 603.54%	-28.32M 23.73%	-167.65M 492.04%	-191.12M 14.00%	-327.77M 71.50%	-14.58M 95.55%
income before tax	6.20M -	64.36M 937.73%	77.63M 20.62%	39.55M 49.05%	302.28M 664.32%	-356.63M 217.98%	-344.75M 3.33%	281.98M 181.79%	-454.43M 261.16%	-331.61M 27.03%	1.48B 547.19%
income tax expense	52.93M -	38.42M 27.41%	18.20M 52.62%	8.95M 50.84%	120.94M 1,251.40%	5.29M 95.62%	2.03M 61.68%	4.46M 119.67%	10.35M 132.21%	15.77M 52.45%	7.75M 50.83%
net income	-46.73M -	25.94M 155.51%	59.43M 129.09%	30.60M 48.51%	181.34M 492.62%	-361.93M 299.58%	-346.78M 4.19%	277.52M 180.03%	-464.77M 267.47%	-347.38M 25.26%	1.48B 524.66%
weighted average shs out	32.99M -	33.32M 1.02%	35.14M 5.46%	38.04M 8.26%	39.98M 5.10%	40.77M 1.98%	40.81M 0.08%	54.05M 32.44%	63.10M 16.76%	54.05M 14.35%	76.71M 41.94%
weighted average shs out dil	32.99M -	33.93M 2.86%	36.16M 6.56%	38.34M 6.05%	40.30M 5.11%	40.77M 1.17%	40.81M 0.08%	54.05M 32.44%	63.10M 16.76%	54.05M 14.35%	76.71M 41.94%
eps	-1.42 -	0.79 155.63%	1.66 110.13%	0.79 52.41%	4.51 470.89%	-8.88 296.90%	-8.50 4.28%	5.13 160.35%	-7.37 243.66%	-6.43 12.75%	19.23 399.07%
epsdiluted	-1.42 -	0.79 155.63%	1.66 110.13%	0.79 52.41%	4.51 470.89%	-8.88 296.90%	-8.50 4.28%	5.13 160.35%	-7.37 243.66%	-6.43 12.75%	19.23 399.07%

COM:BAVARIAN-NORDIC

Bavarian Nordic

Last Close

192.45

22/11 15:59

Market Cap

14.41B

Beta: -

Volume Today

306.12K

Avg: -

Preview